Full text

Turn on search term navigation

© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.

Abstract

Streptomyces are well-known producers of a range of different secondary metabolites, including antibiotics and other bioactive compounds. Recently, it has been demonstrated that “silent” biosynthetic gene clusters (BGCs) can be activated by heterologously expressing transcriptional regulators from other BGCs. Here, we have activated a silent BGC in Streptomyces sp. CA-256286 by overexpression of a set of SARP family transcriptional regulators. The structure of the produced compound was elucidated by NMR and found to be an N-acetyl cysteine adduct of the pyranonaphtoquinone polyketide 3′-O-α-d-forosaminyl-(+)-griseusin A. Employing a combination of multi-omics and metabolic engineering techniques, we identified the responsible BGC. These methods include genome mining, proteomics and transcriptomics analyses, in combination with CRISPR induced gene inactivations and expression of the BGC in a heterologous host strain. This work demonstrates an easy-to-implement workflow of how silent BGCs can be activated, followed by the identification and characterization of the produced compound, the responsible BGC, and hints of its biosynthetic pathway.

Details

Title
Activation and Identification of a Griseusin Cluster in Streptomyces sp. CA-256286 by Employing Transcriptional Regulators and Multi-Omics Methods
Author
Beck, Charlotte 1   VIAFID ORCID Logo  ; Gren, Tetiana 1   VIAFID ORCID Logo  ; Ortiz-López, Francisco Javier 2   VIAFID ORCID Logo  ; Jørgensen, Tue Sparholt 1 ; Carretero-Molina, Daniel 2   VIAFID ORCID Logo  ; Jesús Martín Serrano 2 ; Tormo, José R 2   VIAFID ORCID Logo  ; Oves-Costales, Daniel 2 ; Kontou, Eftychia E 1 ; Mohite, Omkar S 1 ; Mingyar, Erik 3   VIAFID ORCID Logo  ; Stegmann, Evi 3   VIAFID ORCID Logo  ; Genilloud, Olga 2   VIAFID ORCID Logo  ; Weber, Tilmann 1   VIAFID ORCID Logo 

 The Novo Nordisk Foundation Center for Biosustainability, Technical University of Denmark, Kemitorvet, Building 220, 2800 Kongens Lyngby, Denmark; [email protected] (C.B.); [email protected] (T.G.); [email protected] (T.S.J.); [email protected] (E.E.K.); [email protected] (O.S.M.) 
 Fundación MEDINA, Centro de Excelencia en Investigación de Medicamentos Innovadores en Andalucía, Parque Tecnológico de Ciencias de la Salud, Av. Conocimiento, 34, 18016 Granada, Spain; [email protected] (F.J.O.-L.); [email protected] (D.C.-M.); [email protected] (J.M.S.); [email protected] (J.R.T.); [email protected] (D.O.-C.) 
 Department of Microbial Bioactive Compounds, Interfaculty Institute of Microbiology and Infection Medicine, Eberhard Karls Universität Tübingen, Auf der Morgenstelle 28, 72076 Tübingen, Germany; [email protected] (E.M.); [email protected] (E.S.); German Center for Infection Research (DZIF), Partner Site Tübingen, 72076 Tübingen, Germany 
First page
6580
Publication year
2021
Publication date
2021
Publisher
MDPI AG
e-ISSN
14203049
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2596046796
Copyright
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.